GB201417094D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201417094D0
GB201417094D0 GBGB1417094.8A GB201417094A GB201417094D0 GB 201417094 D0 GB201417094 D0 GB 201417094D0 GB 201417094 A GB201417094 A GB 201417094A GB 201417094 D0 GB201417094 D0 GB 201417094D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1417094.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to GBGB1417094.8A priority Critical patent/GB201417094D0/en
Publication of GB201417094D0 publication Critical patent/GB201417094D0/en
Priority to US15/514,416 priority patent/US10144733B2/en
Priority to CA2962321A priority patent/CA2962321A1/en
Priority to EP15767478.9A priority patent/EP3197894B1/en
Priority to AU2015320863A priority patent/AU2015320863B2/en
Priority to PCT/EP2015/071782 priority patent/WO2016046230A1/en
Priority to RU2017114355A priority patent/RU2692775C2/ru
Priority to BR112017006242A priority patent/BR112017006242A2/pt
Priority to CN201580052204.2A priority patent/CN107074851B/zh
Priority to ES15767478T priority patent/ES2811119T3/es
Priority to JP2017516367A priority patent/JP6657196B2/ja
Priority to KR1020177007736A priority patent/KR20170053638A/ko
Priority to US16/165,506 priority patent/US10513517B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB1417094.8A 2014-09-26 2014-09-26 Novel compounds Ceased GB201417094D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1417094.8A GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds
KR1020177007736A KR20170053638A (ko) 2014-09-26 2015-09-22 예를 들면 섬유화 질환의 치료를 위한 알파 v 베타 6 인테그린 길항제로서 나프티리딘 유도체
RU2017114355A RU2692775C2 (ru) 2014-09-26 2015-09-22 Производные нафтиридина в качестве антагонистов альфа v бета 6 интегрина для лечения, в частности, фиброзных заболеваний
CA2962321A CA2962321A1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
EP15767478.9A EP3197894B1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
AU2015320863A AU2015320863B2 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
PCT/EP2015/071782 WO2016046230A1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
US15/514,416 US10144733B2 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases
BR112017006242A BR112017006242A2 (pt) 2014-09-26 2015-09-22 derivados de naftiridina como antagonistas de integrina alfa v beta 6 para o tratamento de, por exemplo, doenças fibróticas
CN201580052204.2A CN107074851B (zh) 2014-09-26 2015-09-22 作为αvβ6整联蛋白拮抗剂用于治疗例如纤维变性疾病的萘啶衍生物
ES15767478T ES2811119T3 (es) 2014-09-26 2015-09-22 Derivados de naftiridina como antagonistas de integrina alfa v beta 6 para el tratamiento de, por ejemplo, enfermedades fibróticas
JP2017516367A JP6657196B2 (ja) 2014-09-26 2015-09-22 線維性疾患などの治療のためのαｖβ６インテグリンアンタゴニストとしてのナフチリジン誘導体
US16/165,506 US10513517B2 (en) 2014-09-26 2018-10-19 Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417094.8A GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
GB201417094D0 true GB201417094D0 (en) 2014-11-12

Family

ID=51901231

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1417094.8A Ceased GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds

Country Status (12)

Country Link
US (2) US10144733B2 (enExample)
EP (1) EP3197894B1 (enExample)
JP (1) JP6657196B2 (enExample)
KR (1) KR20170053638A (enExample)
CN (1) CN107074851B (enExample)
AU (1) AU2015320863B2 (enExample)
BR (1) BR112017006242A2 (enExample)
CA (1) CA2962321A1 (enExample)
ES (1) ES2811119T3 (enExample)
GB (1) GB201417094D0 (enExample)
RU (1) RU2692775C2 (enExample)
WO (1) WO2016046230A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
US20190144547A1 (en) * 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
JP2019510020A (ja) 2016-03-15 2019-04-11 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 害虫を防除するための置換スルホニルアミド類
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
BR112019009245A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
PL3538525T3 (pl) 2016-11-08 2022-09-12 Bristol-Myers Squibb Company 3-podstawione kwasy propionowe jako inhibitory integryny alfa v
MA46745A (fr) 2016-11-08 2021-03-31 Bristol Myers Squibb Co Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
BR112019009129A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina
JP7220653B2 (ja) * 2016-11-08 2023-02-10 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロールアミド
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
CN116283977A (zh) 2017-02-28 2023-06-23 莫菲克医疗股份有限公司 αvβ6整合蛋白的抑制剂
AU2018365793A1 (en) 2017-11-07 2020-06-18 Bristol-Myers Squibb Company Pyrrolopyrazine derivatives as alpha V integrin inhibitors
TWI857918B (zh) * 2018-08-29 2024-10-01 美商莫菲克醫療股份有限公司 αvβ6整合素之抑制劑
SG11202101913PA (en) 2018-08-29 2021-03-30 Morphic Therapeutic Inc INHIBITING aV ß6 INTEGRIN
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
EP4490042A1 (en) 2022-03-08 2025-01-15 Equashield Medical Ltd. Fluid transfer station in a robotic pharmaceutical preparation system
CN120731091A (zh) 2022-12-14 2025-09-30 阿尔尼拉姆医药品有限公司 用于肝外递送的α-Vβ-6(αvβ6)整合素配体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100397A3 (en) 1997-12-17 2002-10-28 Merck & Co Inc Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AU749351B2 (en) 1999-06-02 2002-06-27 Merck & Co., Inc. Alpha V integrin receptor antagonists
AU748949B2 (en) 1999-06-23 2002-06-13 Merck & Co., Inc. Integrin receptor antagonists
JP2003510360A (ja) * 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
ATE245645T1 (de) 1999-11-08 2003-08-15 Merck & Co Inc Verfahren und zwischenprodukte zur herstellung von imidazolinon alpha v integrin antagonisten
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
DE60126496T2 (de) 2000-07-26 2007-11-15 Merck & Co., Inc. Alpha v integrin-rezeptor-antagonisten
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
CA2432504A1 (en) 2001-01-03 2002-07-11 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
US7705018B2 (en) 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2009055418A1 (en) 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2976634C (en) 2015-02-19 2023-10-17 Scifluor Life Sciences, Inc Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
US10513517B2 (en) 2019-12-24
US20190048005A1 (en) 2019-02-14
ES2811119T3 (es) 2021-03-10
WO2016046230A1 (en) 2016-03-31
KR20170053638A (ko) 2017-05-16
RU2692775C2 (ru) 2019-06-27
AU2015320863A1 (en) 2017-03-09
RU2017114355A (ru) 2018-10-29
US10144733B2 (en) 2018-12-04
EP3197894A1 (en) 2017-08-02
EP3197894B1 (en) 2020-06-03
AU2015320863B2 (en) 2018-09-06
RU2017114355A3 (enExample) 2019-01-14
CA2962321A1 (en) 2016-03-31
CN107074851A (zh) 2017-08-18
JP6657196B2 (ja) 2020-03-04
BR112017006242A2 (pt) 2017-12-12
JP2017528504A (ja) 2017-09-28
US20170291899A1 (en) 2017-10-12
CN107074851B (zh) 2020-01-10

Similar Documents

Publication Publication Date Title
IL250345B (en) new compounds
IL250592A0 (en) new compounds
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201417011D0 (en) Novel compounds
GB201417094D0 (en) Novel compounds
GB201405991D0 (en) Novel compounds
GB201417018D0 (en) Novel compounds
GB201402431D0 (en) Compounds
SG11201606693SA (en) Novel compounds
GB201406591D0 (en) Compounds
GB201411236D0 (en) Novel compounds
GB201411239D0 (en) Novel compounds
GB201406956D0 (en) Compounds
GB201404987D0 (en) Compounds
GB201404002D0 (en) Novel compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
IL248983A0 (en) new compounds
GB201419102D0 (en) Novel compounds
GB201407695D0 (en) Compounds
GB201405361D0 (en) Compounds
ZA201605726B (en) Novel compounds
GB201421834D0 (en) Novel compounds
GB201421784D0 (en) Novel compounds
GB201417041D0 (en) Novel compounds
GB201417021D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)